PTP 001
Alternative Names: MOTYS; PTP-001Latest Information Update: 24 Nov 2022
At a glance
- Originator Bioventus
- Class Antirheumatics; Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 30 Jun 2022 Discontinued - Phase-I for Osteoarthritis in USA (Intra-articular)
- 30 Jun 2022 Discontinued - Phase-II for Osteoarthritis (In the elderly, In adults) in Canada (Intra-articular)
- 30 Sep 2021 Phase-II clinical trials in Osteoarthritis (In adults, In the elderly) in Canada (Intra-articular) (NCT05100225)